加载中
NASDAQHealthcareBiotechnology
最新数据
US$4.01
−US$0.35 · -8.03%
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
收盘时
US$4.01
−US$0.35 · -8.03%
盘后
US$4.01
US$0.00 · 0.00%
10月12日 19:59 ET
盘中时间采用ET。市场数据可能有所延迟。
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
日内区间
当前US$4.01
52周区间
当前US$4.01
盘中时间采用ET。市场数据可能有所延迟。
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
日内区间
当前US$4.01
52周区间
当前US$4.01
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7468.1万 USD | 5883.9万 USD | 4387.6万 USD | 3968.1万 USD | 1000万 USD |
| 销货成本 | 1.21亿 USD | 4523.8万 USD | 4258.7万 USD | 4827.5万 USD | — |
| 毛利 | −4627.3万 USD | 1360.1万 USD | 128.9万 USD | −859.4万 USD | 1000万 USD |
| 研究与开发 | 4.25亿 USD | 3.14亿 USD | 2.41亿 USD | 1.56亿 USD | 1.35亿 USD |
| 销售、一般及管理费用 | 1.77亿 USD | 1.78亿 USD | 1.11亿 USD | 8159.9万 USD | 5768.2万 USD |
| 营业费用 | 6.02亿 USD | 4.93亿 USD | 3.51亿 USD | 2.37亿 USD | 1.93亿 USD |
| 利息收入 | 2278.8万 USD | 1575.8万 USD | 1911.6万 USD | 625.4万 USD | 7.3万 USD |
| 利息支出 | 181万 USD | 157.2万 USD | 9.7万 USD | 5.5万 USD | 295.2万 USD |
| 折旧和摊销 | 8370.1万 USD | 3649.4万 USD | 2440.2万 USD | 1175.6万 USD | 840.5万 USD |
| 营业利润 | −6.48亿 USD | −4.79亿 USD | −3.5亿 USD | −2.46亿 USD | −1.83亿 USD |
| 净利润 | −6.45亿 USD | −4.64亿 USD | −3.28亿 USD | −2.39亿 USD | −1.86亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.30
上涨空间 32.17%报告持有此股票敞口的交易所交易基金。
ARK Innovation ETFARKK9298.25万1.39%55.62亿 USD0.75%US$88.02-1.79%
State Street SPDR S&P Biotech ETFXBI7130.39万0.72%98.74亿 USD0.35%US$151.4-1.54%
ARK Genomic Revolution ETFARKG6421.09万3.01%15.57亿 USD0.75%US$49.48-3.55%
iShares Russell 2000 ETFIWM5856.25万0.07%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI5404.89万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB3897.36万0.02%1853亿 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK2232.72万0.05%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF2071.17万0.02%954亿 USD0.05%US$233.52-0.63%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
